Time to back up the truckWhen people are worried, it's time to buy, dixit Warren Buffett.The big problem with PLI is the lack of institutional shareholding. More than half of shareholders are private investors.Many of them don't understand how biotechnology companies work and they are not prepared to deal with a marathon,so they abandonned half the way or after 80% of the way when the finish line is in sight but they are not able to figure out that this line is only some 100 meters away when you consider all the way done by PLI in the last decade.It is symptomatic of the market psychology and with big money playing short for a while, there is no counterpart to balance the count (Institutions). Ryplazim will be on market in 2018 for PG deficiency (2000 patients) and clinical trials for many indications will follow the course:
Diabetic Foot Ulcer: potential:500,000 patients a year (U.S.)
Tympanic Repair : potential: 80,000 patients a year (U.S.)
Acquired Acute DF : potential :100,000 patients a year (U.S.)
Ophtalmic indication: potential : 100,000 patients a year (U.S.)
Severe Burns indication: 15,000 patients a year (U.S.)
So many physicians will have the potential to administer PG for Off Label applications and will contribute to the basin of knowledge on this incredible protein. For one, I think that PLI will have a problem of PG shortage in 2020 or 2021 if you consider the number of amputations (45,000) for Diabetic foot ulcer only for the U.S.
How much money will make PLI at this time will depend on how the different deals will be done. So for my part, I prefer to wait some more time and give the opportunity to the management to sign them in a way to preserve I.P. and shareholders money on a long term basis. Thomvest has understood it but most of the people on this B.B. don't have the balls to deal with Biotech stocks.